BIOAF Bioasis Technologies Inc (CE)

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 16, 2014) - biOasis Technologies Inc. (TSX-VENTURE:BTI) (OTCQX:BIOAF) (the "Company") is pleased to announce that is has retained Gale Capital Corporation ("Gale Capital") effective June 15, 2014 to assist the Company with its shareholder relations activities and investor awareness program.

Gale Capital will help by cultivating productive dialogue with analysts, brokers, potential investors and current shareholders for the purpose of expanding the Company's exposure within the Canadian and American investment community. Gale Capital will also assist in the development and implementation of an investor relations and communications program for purposes of attracting prospective investors to the Company and strengthening the Company's profile within the investment community.

"We are very pleased to be engaging Gale Capital and are very impressed with their overall approach and strategy as discussed with the Company" said Rob Hutchison, Chief Executive Officer of biOasis Technologies Inc. "In addition internally we have hired a new member of the biOasis team, Ms. Tiffany Tolmie, whom along with a number of corporate responsibilities will act as our corporate communications liaison to our shareholders, a role that will go a great way to increase external communications and support the efforts of the Gale group".

The initial term of this investor relations agreement is until June 15, 2015, which the parties may extend by mutual consent, and either party may terminate the agreement after September 15, 2014 with 30 days written notice. The Company will pay a monthly fee in advance of CAD $6,000. Gale Capital will be granted 200,000 incentive share purchase options expiring on June 15, 2016 exercisable at $1.23. The stock options will vest over 12 months, with 50,000 options vesting on September 15, 2014, 50,000 on December 15, 2014, 50,000 on March 15, 2015 and 50,000 on June 15, 2015. The options follow the guidelines as set out in Company's stock option plan and as set by TSX Venture Policy. The agreement and options grant and terms are subject to the approval of the TSX Venture Exchange.

About Gale Capital

Gale capital has provided quality investor relations services to publicly traded companies globally since 1993. Their team of experienced professionals, key affiliates and media personnel design and execute custom corporate communications programs to meet individual company and shareholder requirements

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis' proprietary brain delivery platform, the company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain disorders such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the OTCQX under the symbol BIOAF and on the TSX Venture

Exchange under the symbol "BTI". For more information about the company please visit www.bioasis.ca.

Herceptin® is a registered trademark of Genentech/Roche.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words

"believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward -looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Rob Hutchison Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release"

Company Contact:Rob Hutchison, Chairman & CEObiOasis Technologies Inc.778-383-3280info@bioasis.caTiffany Tolmie, Corporate Communications LiaisonbiOasis Technologies Inc.778 383 3280Tiffany@bioasis.caInvestor Relations Contact:Gale Capital Corporation604-200-1480info@galecpital.com

Bioasis Technologies (CE) (USOTC:BIOAF)
Historical Stock Chart
From Nov 2024 to Dec 2024

Bioasis Technologies (CE) (USOTC:BIOAF)
Historical Stock Chart
From Dec 2023 to Dec 2024